research Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm
CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
Search
forLearn
0 / 0 results — no results
Research
5 / 197 results 
research Safety and Patient-Reported Outcomes in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated With CDK4/6 Inhibitors in China: A Cross-Sectional Study
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research Fatigue, Alopecia, and Stomatitis Among Patients With Breast Cancer Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Systematic Review and Meta-Analysis
Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
research Retrospective Cohort Study of CDK4/6-Inhibitor-Induced Alopecia in Patients With Breast Cancer
CDK4/6 inhibitors may cause hair loss in breast cancer patients.
research Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study
Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
Community Join
0 / 0 results — no results